US Authorizes Juul To Market Vaping Products
Juul won the new marketing granting orders (MGO) after submitting more than 110 scientific studies to the agency, the company said in a statement.
The decision means Juul can continue to sell products that have been on the US market but in regulatory limbo following earlier actions by the FDA.
"Following rigorous evaluation of the data, FDA decided that an MGO for the Juul System was 'appropriate for the protection of public health' -- the standard required by statute for authorization," Juul said.
Juul has argued that its vaping products provide a public health benefit by shifting smokers away from combustible tobacco products closely linked to deadly illnesses.
But the company has been criticized for its marketing practices, agreeing to pay $438.5 million in a 2022 settlement with 34 US states to resolve accusations of marketing to underage smokers.
The FDA's move allows Juul to sell five products in all: the Juul device and capsules for the "Virginia Tobacco" and menthol flavor, each in versions with three or five percent nicotine concentration, said a spokesperson for the US Department of Health and Human Services.
The products needed to meet the standard set under a 2009 smoking prevention law showing that the benefits of switching to a potentially less harmful product is "sufficient to outweigh the risks of the product," including to anyone not using tobacco products, the spokesperson said.
The applicant submitted data "demonstrating high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products."
But the agency's determination "does not mean these tobacco products are safe, nor are they 'FDA approved,'" said the spokesperson, who added that the agency will continue to monitor Juul's compliance with youth marketing restrictions.
Juul survived a difficult stretch after the FDA ordered it to halt sales in June 2022 because of health questions, although the decision was adminsistratively suspended by the same agency shortly thereafter.
In June 2024, the FDA formally rescinded its June 2022 order, shifting the matter back into "pending" status while a substantive review continued.
The FDA's action on Thursday "confirms that these products are now authorized to remain on the market," said a Juul spokesman.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
17-07-2025
- Int'l Business Times
US Authorizes Juul To Market Vaping Products
Juul Labs said Thursday that the US Food and Drug Administration had officially authorized the e-cigarette maker to market its vaping system and refill capsules in the United States. Juul won the new marketing granting orders (MGO) after submitting more than 110 scientific studies to the agency, the company said in a statement. The decision means Juul can continue to sell products that have been on the US market but in regulatory limbo following earlier actions by the FDA. "Following rigorous evaluation of the data, FDA decided that an MGO for the Juul System was 'appropriate for the protection of public health' -- the standard required by statute for authorization," Juul said. Juul has argued that its vaping products provide a public health benefit by shifting smokers away from combustible tobacco products closely linked to deadly illnesses. But the company has been criticized for its marketing practices, agreeing to pay $438.5 million in a 2022 settlement with 34 US states to resolve accusations of marketing to underage smokers. The FDA's move allows Juul to sell five products in all: the Juul device and capsules for the "Virginia Tobacco" and menthol flavor, each in versions with three or five percent nicotine concentration, said a spokesperson for the US Department of Health and Human Services. The products needed to meet the standard set under a 2009 smoking prevention law showing that the benefits of switching to a potentially less harmful product is "sufficient to outweigh the risks of the product," including to anyone not using tobacco products, the spokesperson said. The applicant submitted data "demonstrating high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products." But the agency's determination "does not mean these tobacco products are safe, nor are they 'FDA approved,'" said the spokesperson, who added that the agency will continue to monitor Juul's compliance with youth marketing restrictions. Juul survived a difficult stretch after the FDA ordered it to halt sales in June 2022 because of health questions, although the decision was adminsistratively suspended by the same agency shortly thereafter. In June 2024, the FDA formally rescinded its June 2022 order, shifting the matter back into "pending" status while a substantive review continued. The FDA's action on Thursday "confirms that these products are now authorized to remain on the market," said a Juul spokesman.
Int'l Business Times
02-07-2025
- Int'l Business Times
RFK Jr Declares 'Stop Trusting Experts' as He Pledges AI Revamp for HHS: 'You Can Do Drug Approvals Quickly With AI'
Health Secretary Robert F. Kennedy Jr. is facing renewed scrutiny after declaring the public should "stop trusting experts" while unveiling his plans to integrate artificial intelligence across federal health agencies, including accelerating drug approvals at the FDA. Speaking on "The Tucker Carlson Show" on Monday, Kennedy said he is leading an "AI revolution" within the Department of Health and Human Services, enlisting tech talent from Silicon Valley to overhaul outdated systems like the Vaccine Adverse Event Reporting System (VAERS). His goal, he explained, is to automate and streamline processes like drug approvals without relying on animal testing, arguing that AI tools can achieve results "very, very quickly." "We are at the cutting edge of AI," Kennedy said. "We're implementing it in all of our departments. At FDA, we're accelerating drug approvals so that you don't need to use primates or even animal models. You can do the drug approvals very, very quickly with AI." Kennedy's remarks included sweeping criticisms of the scientific establishment, including the assertion that trusting public health experts is "not a feature of science," but instead akin to "totalitarianism." He claimed that Americans were wrongly discouraged from conducting their own COVID-19 research, adding, "We need to stop trusting the experts, right?" While Kennedy did not specify which AI systems would be used for drug approvals, he suggested the agency would move away from traditional clinical models in favor of simulated testing. During the interview, he repeated misleading claims about COVID-19 vaccine trials, suggested former Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci should face legal consequences and called for a national "truth commission" to investigate the government's pandemic response. While Kennedy says the agency is actively recruiting engineers and data scientists for his AI initiative, he has yet to announce any formal rule changes or provide technical guidance for how AI would meet existing regulatory standards. Originally published on Latin Times
Int'l Business Times
30-06-2025
- Int'l Business Times
Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington
Travere Therapeutics stock has climbed roughly 110% from its 52-week low of around $6.80 to $14.30, as hedge funds such as Armistice Capital, Driehaus Capital Management, and Wellington Management have built positions around the company's rare kidney disease therapeutics. The biopharmaceutical company's lead asset, FILSPARI, has achieved full FDA approval for IgA nephropathy (IgAN), or Berger's disease. Fourth quarter 2024 revenue reached $73.5 million, driven by FILSPARI's momentum in kidney disease treatment, while the company maintained a robust $370.7 million cash position. The performance has attracted attention from both specialized healthcare investors and broader institutional managers. FILSPARI and Regulatory Momentum FILSPARI received full FDA approval in the third quarter of 2024 as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN. The regulatory achievement transformed the drug from an accelerated approval based on surrogate endpoints to full approval based on clinically meaningful outcomes. It initially received accelerated approval on February 17, 2023, for reducing proteinuria in adults with primary IgAN, with commercial availability beginning the week of February 27, 2023. Converting to full approval within 18 months reflects both the strength of clinical data and the company's regulatory execution capabilities. The FDA recently accepted for review Travere's supplemental New Drug Application requesting modification of liver monitoring for FILSPARI in IgAN, with a target action date of August 28, 2025. Reducing monitoring requirements could expand patient access and physician adoption, factors that institutional investors monitor closely when evaluating commercial potential. Pipeline Expansion Beyond IgAN, Travere is developing sparsentan to treat focal segmental glomerulosclerosis (FSGS), another rare kidney disease that often leads to kidney failure. FSGS damages the tiny filters in the kidneys, causing protein to leak into urine. Following meetings with the FDA, the company plans to submit a supplemental New Drug Application for FSGS treatment around the end of the first quarter of 2025, using data from two major clinical studies called DUPLEX and DUET. If approved, sparsentan would become the first FDA-approved medicine specifically for FSGS patients, giving Travere a significant competitive advantage in treating this rare condition. The company is also developing a drug called pegtibatinase for homocystinuria, a genetic disorder where the body cannot properly break down certain amino acids. This buildup can damage blood vessels and cause developmental delays. International expansion could provide another growth avenue. Travere's partner Renalys Pharma expects results from its Phase 3 clinical trial of sparsentan for IgAN treatment in Japan during the second half of 2025. This partnership allows Travere to enter the Japanese market without direct investment while receiving milestone payments and future royalties if the treatment succeeds. Institutional Investment Travere Therapeutics has 447 institutional owners holding a total of 117,537,916 shares, with the largest shareholders including Armistice Capital, BlackRock Inc., Janus Henderson Group, Vanguard Group Inc., and Driehaus Capital Management. The institutional ownership structure spans both passive index funds and active specialty investors. Armistice Capital owns approximately 8.9 million shares, accounting for 2.38% of the hedge fund's portfolio. Other institutional participants include Wellington Management Group, which acquired a new stake during the fourth quarter, purchasing 33,493 shares valued at approximately $583,000. Emerald Advisers LLC raised its stake by 8.4% during the fourth quarter to 2,125,744 shares worth $37.03 million. Several major institutional investors expanded their Travere positions during the fourth quarter. Rock Springs Capital Management added 289,173 shares, bringing its total to nearly 5 million shares valued at $86.6 million. Renaissance Technologies increased its stake by 28.5% to 2.4 million shares worth $42 million. Driehaus Capital Management made the largest percentage increase, adding over 1.9 million shares for a 608% jump. The firm now holds 2.2 million shares valued at $38.6 million. Jacobs Levy Equity Management grew its position by 37% to 2.2 million shares worth $37.9 million, while Emerald Advisers added 165,085 shares to reach 2.1 million shares valued at $37 million. The combination of new entrants and existing shareholders increasing positions is a sign of continuing investor interest amid the stock's strong performance over the past year. Financial Position and Development Goals Travere ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities. The financial position supports ongoing commercial activities and clinical development through multiple regulatory catalysts without requiring additional equity financing. As of June 2025, Travere's market capitalization stood at approximately $1.27 billion. Meanwhile, the rare disease therapeutic market presents unique investment characteristics that attract institutional capital. Institutional investors evaluate rare disease companies based on regulatory expertise, commercial execution capabilities, and pipeline diversification. Travere's progression from accelerated to full approval demonstrates regulatory competence, while consistent patient start form growth is a sign of commercial execution. The company's advancement of multiple indications for sparsentan and development of pegtibatinase provide portfolio diversification within the rare disease focus. Investment from hedge funds such as Armistice Capital, Driehaus Capital Management, and Wellington Management reflects institutional positions on Travere's ability to execute on its rare disease focus. The combination of commercial revenue, regulatory momentum, and pipeline expansion opportunities continues to attract institutional capital to the company's equity.
